The challenges of neoadjuvant trials, what we learnt from NAXIVA
NAXIVA is the first clinical trial to evaluate neoadjuvant downstaging of patients with the unique biological phenomenon of venous tumour thrombus in kidney cancer. But what did we learn beyond the endpoints?